Stocktoria
Entrada Therapeutics, Inc. TRDA
Entrada Therapeutics, Inc. (TRDA) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $25.4M at a -565.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.747 |
| Retained earnings / assets | -0.724 |
| EBIT / assets | -0.418 |
| Equity / liabilities | 4.297 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | 2/9 | 4.24 | — | -87.9% |
| CELU | Celularity Inc | 1/9 | — | — | -51% |
| ALMS | ALUMIS INC. | 1/9 | -7.78 | — | — |
| CUE | Cue Biopharma, Inc. | 4/9 | — | — | — |
| NAMS | NewAmsterdam Pharma Co N.V. | 2/9 | 8.19 | — | -50.6% |
| SCYX | SCYNEXIS INC | 4/9 | -13.88 | — | — |
| FHTX | Foghorn Therapeutics Inc. | 1/9 | -10.28 | — | +36.8% |
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
FAQ
Is TRDA financially healthy?
Entrada Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does TRDA pay a dividend?
No, Entrada Therapeutics, Inc. does not currently pay a dividend.
How profitable is TRDA?
In FY2025, Entrada Therapeutics, Inc. had a net margin of -565.5% and a return on equity of -47.0%.
What is the analyst price target for TRDA?
The average Wall-Street price target for Entrada Therapeutics, Inc. is $18.75, about 144.5% above the recent price, from 4 analysts.
Is TRDA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Entrada Therapeutics, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.